Finoriq research workspace
Roivant Sciences Ltd. (ROIV) Institutional Holdings & 13F Ownership
In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP). Review ROIV institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
- Company
- Roivant Sciences Ltd. (ROIV)
- Ticker
- ROIV
- Market Cap
- $24.7B
- Latest Price
- $34.28
- Industry
- Biotech & Pharma
Roivant Sciences Ltd. (ROIV) Top Institutional Holders
Top current 13F holders indexed for Roivant Sciences Ltd. (ROIV). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Viking Global InvestorsCIK 0001103804 | $184.3M | 0.52% | Filing2026-05-15 |
| 2 | David EinhornCIK 0001489933 | $59.6M | 1.9% | Filing2026-05-15 |
| 3 | Lee AinslieCIK 0000934639 | $45.1M | 0.52% | Filing2026-05-15 |
| 4 | Joel GreenblattCIK 0001510387 | $39.2M | 0.12% | Filing2026-05-15 |
| 5 | Ron BaronCIK 0001017918 | $3.5M | 0.01% | Filing2026-05-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.